- Home
- PHAR vs BCYC Comparison
PHAR vs BCYC Comparison
Compare PHAR & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- BCYC
- Stock Information
- Founded
- PHAR 1988
- BCYC 2009
- Country
- PHAR Netherlands
- BCYC United Kingdom
- Employees
- PHAR N/A
- BCYC N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- PHAR Health Care
- BCYC Health Care
- Exchange
- PHAR Nasdaq
- BCYC Nasdaq
- Market Cap
- PHAR 587.5M
- BCYC 581.7M
- IPO Year
- PHAR N/A
- BCYC 2019
- Fundamental
- Price
- PHAR $10.03
- BCYC $8.34
- Analyst Decision
- PHAR Strong Buy
- BCYC Buy
- Analyst Count
- PHAR 3
- BCYC 10
- Target Price
- PHAR $30.00
- BCYC $25.00
- AVG Volume (30 Days)
- PHAR 3.0K
- BCYC 401.9K
- Earning Date
- PHAR 05-08-2025
- BCYC 05-01-2025
- Dividend Yield
- PHAR N/A
- BCYC N/A
- EPS Growth
- PHAR N/A
- BCYC N/A
- EPS
- PHAR N/A
- BCYC N/A
- Revenue
- PHAR $320,708,000.00
- BCYC $25,722,000.00
- Revenue This Year
- PHAR $12.39
- BCYC N/A
- Revenue Next Year
- PHAR $9.84
- BCYC $0.27
- P/E Ratio
- PHAR N/A
- BCYC N/A
- Revenue Growth
- PHAR 24.13
- BCYC N/A
- 52 Week Low
- PHAR $6.65
- BCYC $6.10
- 52 Week High
- PHAR $11.07
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- PHAR 71.76
- BCYC 49.88
- Support Level
- PHAR $8.60
- BCYC $7.95
- Resistance Level
- PHAR $10.28
- BCYC $9.55
- Average True Range (ATR)
- PHAR 0.30
- BCYC 0.72
- MACD
- PHAR 0.17
- BCYC 0.05
- Stochastic Oscillator
- PHAR 88.79
- BCYC 43.98
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.